Recent Advances and Future Directions in Lung Cancer — With Dr Ibiayi Dagogo-Jack and Stephen Liu (Proceedings from a Symposium in Partnership with NCOA and SCOS)
Lung Cancer Update
00:00
TDXD Versus TDM1 in the First Line Setting?
Soderasib has response rates in the 40% median PFS at around six months. And that's what Soderas have got there first. Trastuzumab, Diracca is not approved for Amplified non-tumultil lung cancer. We need more data personally before I move these to the first line setting over chemotherapy or immunotherapy. For all intents and purposes, efficacy-wise, I think they're comparable with this drug.
Transcript
Play full episode
